Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 40S ribosomal subunit is the smaller component of the eukaryotic 80S ribosome, playing a fundamental role in the initiation and accuracy of protein translation (NCBI, 2023). It consists of the 18S ribosomal RNA (rRNA) and approximately 33 ribosomal proteins (RPS), which together form the framework for mRNA binding and tRNA selection (UniProt, 2024). During translation initiation, the 40S subunit binds to the mRNA 5' cap and scans for the AUG start codon, a process regulated by various eukaryotic initiation factors (eIFs). Beyond its role in mature ribosomes, the assembly of pre-40S particles in the nucleolus is a complex, highly regulated process essential for cellular growth and proliferation (PubMed, 2022). Mutations in the proteins or assembly factors of the 40S subunit lead to ribosomopathies, such as Diamond-Blackfan anemia and 5q- syndrome, characterized by bone marrow failure and increased cancer risk (NIH, 2023). Furthermore, many viruses, including Hepatitis C and Poliovirus, hijack the 40S subunit via Internal Ribosome Entry Sites (IRES) to bypass host translation controls (Wikipedia, 2024). While most clinical antibiotics target bacterial ribosomes, the 40S subunit is a target for specific toxins and experimental anti-tumor agents like emetine and pactamycin, which inhibit translation by interfering with the decoding site or translocation (PubChem, 2024).
Inhibition of translation initiation by preventing mRNA scanning or eIF recruitment; interference with aminoacyl-tRNA binding at the A-site; blockage of the translocation step during elongation (PubChem, 2024; PubMed, 2022).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 40S ribosomal subunit (40S).